Compare BlackBerry Limited (BB) vs Cytokinetics Inc (CYTK) Price & Performance

BlackBerry (BB) trades at $8.98, up 2.28% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings beats and a positive 2026 net income forecast of $60M signal a turnaround, though 2025 saw a net loss of $79M. The stock's valuation remains elevated with a P/E of 89.8 and P/S of 9.22. News highlights growth in QNX and secure communications, with the stock gaining 125% year-to-date as of August 2026, though it has pulled back 35% from its peak.

The outlook hinges on execution of growth in QNX and secure communications, with FY2027 guidance suggesting 11% revenue growth and 20% adjusted EBITDA margin expansion. Risks include premium valuation, cyclical industry exposure, and reliance on long-dated QNX royalties. Analyst consensus is cautious with 85.7% hold ratings, but a $10.50 price target implies potential upside if operational improvements materialize.

Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.

The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.